A LYSA Phase Ib Study of tazemetostat (EPZ-6438) plus R-CHOP in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients with poor prognosis features.

CONCLUSIONS: The RP2D of tazemetostat combined with R-CHOP is 800 mg BID. The association presents safety and PK comparable to R-CHOP alone. Preliminary efficacy data are encouraging and further investigations in phase 2 trial are warranted.
PMID: 32122924 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - March 1, 2020 Category: Cancer & Oncology Authors: Sarkozy C, Morschhauser F, Dubois S, Molina T, Michot JM, Cuillière-Dartigues P, Suttle B, Karlin L, Le Gouill S, Picquenot JM, Dubois R, Tilly H, Herbaux C, Jardin F, Salles G, Ribrag V Tags: Clin Cancer Res Source Type: research